Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion type Assertion NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_head.
- NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion description "[A combined ELISA for both LY6K and CEA classified 64.7% of lung adenocarcinoma patients as positive, and the use of both LY6K and CYFRA 21-1 increased sensitivity in the detection of lung squamous cell carcinomas and ESCCs up to 70.4% and 52.5%, respectively, whereas the false positive rate was 6.8% to 9.5%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_provenance.
- NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion evidence source_evidence_literature NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_provenance.
- NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion SIO_000772 18089789 NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_provenance.
- NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion wasDerivedFrom befree-20140225 NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_provenance.
- NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_assertion wasGeneratedBy ECO_0000203 NP893824.RAqcqF02XrIn3ymM55-jio-eEBgLHgv1macEnM2COartQ130_provenance.